CAGNETTA, ANTONIA
 Distribuzione geografica
Continente #
EU - Europa 4.331
Totale 4.331
Nazione #
IT - Italia 4.331
Totale 4.331
Città #
Genova 3.199
Genoa 570
Rapallo 522
Vado Ligure 32
Bordighera 8
Totale 4.331
Nome #
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 168
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 166
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment 162
Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors and DNA repair. 162
APO866 activity in hematologic malignancies: a preclinical in vitro study. 149
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 139
Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. 128
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. 127
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more. 127
New insights into biology of chronic myeloid leukemia: implications in therapy. 120
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 118
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 118
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 117
Nicotinamide Phosphoribosyltransferase As A Target In Inflammation-Related Disorders. 115
ANTITUMOR ACTIVITY OF NAMPT INHIBITION AND SYNERGY WITH CYCLOSPORIN A AND HDACIS TO PROMOTE APOPTOSIS IN PRIMARY LEUKEMIC CELLS 114
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. 113
Targeting NAD(+) Salvage Pathway Induces Autophagy in Multiple Myeloma Cells 109
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 109
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 109
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 108
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 106
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications 102
Intracellular NAD+ depletion induces autophagic-death in Multiple Myeloma cells 102
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 102
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 102
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells via mTORC1 and Extracellular Signal-Regulated Kinase (ERK1/2) Inhibition 101
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. 101
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 101
MiR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth 94
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 90
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma 90
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma 88
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib 88
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. 83
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 81
Synergistic Interaction Between P-glycoprotein Inhibitors and APO866 in Primary Leukemic Cells 73
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells 66
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 59
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 47
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 47
The non-coding RNA landscape of plasma cell dyscrasias 39
A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML 27
Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma 18
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation 17
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients 17
The non-coding RNA landscape of plasma cell dyscrasias 10
Daratumumab in the treatment of C3 glomerulopathy with monoclonal gammopathy: a case report and literature review 8
Totale 4.437
Categoria #
all - tutte 14.068
article - articoli 14.068
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.136


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.214 0 27 53 123 127 164 167 103 122 165 123 40
2020/2021435 22 37 20 34 52 27 27 40 31 56 51 38
2021/2022566 21 26 37 70 25 47 30 113 28 52 30 87
2022/2023648 72 71 9 76 106 93 6 39 89 12 71 4
2023/2024433 14 58 14 57 43 91 23 45 12 5 29 42
2024/202558 43 15 0 0 0 0 0 0 0 0 0 0
Totale 4.437